“…For the spatial distribution of ACE2 in human brain, we found ACE2 may be relatively high (Z score>1) expressed in many important brain nuclei as follows: (1) brain areas where located the neural cell bodies of different neuromodulators, including dopaminergic nuclei (midbrain reticular formation, VTA and substantia nigra), serotoninergic nuclei (midbrain raphe nuclei) (Pollak Dorocic et al, 2014), histaminergic nuclei (tuberomammillary nucleus, TM) (Hu and Chen, 2017), and norepinephrinergic nuclei (locus ceruleus) (Wood and Valentino, 2017); (2) Brain areas participating in important physiologic functions, including posterior hypothalamic area (involved in the control of the sleep-wake cycle, cardiovascular regulation and the expression of defensive-aggressive behavior)(Katagiri et al, 2013), paraventricular nuclei of thalamus (involved in the control of wakefulness, feeding, appetitive motivation, drug addiction, regulation of stress and negative emotional behavior, and epilepsy)(Chen et al, 2020; Ren et al, 2018), paraventricular nucleus of the hypothalamus (neuroendocrine neurons regarding oxytocin, vasopressin, corticotropin-releasing hormone, thyrotropin-releasing hormone)(Qin et al, 2018), and lateral hypothalamic area (the central regulation of hunger, thirst, rewarding, and autonomic nervous system) (Stuber and Wise, 2016); (3) Other brain areas, including amygdalo-hippocampal transition area (related to fear expression) (Fujisaki et al, 2004), hippocampal CA2 field (related to learning and memory) (Dudek et al, 2016), fastigial nucleus (related to body and eye movements) (Zhang et al, 2016), and piriform cortex (related to the sense of smell and epilepsy) (Cheng et al, 2020). Thus, our results may provide some clues to further study on the brain infection of SARS-CoV-2 in the COVID-19 patients, and suggesting SARS-CoV-2 might be able to result in serious CNS symptoms in COVID-19 patients (if it could infect these important brain areas by binding ACE2).…”